SEC Form 4 · accession 0001943192-26-000006
Travere Therapeutics, Inc. · TVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher R. Cline
Officer — CHIEF FINANCIAL OFFICER
Period of report
Sep 15, 2026
Accepted (ET)
Sep 17, 2026 · 9:30 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001438533
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 15, 2026 | M | 20,000 | $17.44 | A | 138,016 | D | |
| Common StockF2 | Sep 15, 2026 | S | 27,473 | $61.9969 | D | 110,543 | D | |
| Common StockF3 | Sep 15, 2026 | S | 20,735 | $62.6079 | D | 89,808 | D | |
| Common StockF4 | Sep 15, 2026 | S | 1,900 | $63.6865 | D | 87,908 | D | |
| Common Stock | Sep 15, 2026 | S | 400 | $65.31 | D | 87,508 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee stock option (right to buy)F5 | $17.44 | Sep 15, 2026 | M | 20,000 | D | — | May 17, 2027 | Common Stock | 20,000 | 0 | D |
Explanation of responses
- F1This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027.
- F2The weighted average sale price for the transaction reported was $61.9969, and the range of prices were between $61.38 and $62.37. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- F3The weighted average sale price for the transaction reported was $62.6079, and the range of prices were between $62.38 and $63.30. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- F4The weighted average sale price for the transaction reported was $63.6865, and the range of prices were between $63.59 and $63.86. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- F5The stock option is fully vested and exercisable.